新辅助化疗对乳腺癌Cerb-B2表达的影响及其临床意义  

Influence and significance of Neo-adjuvant chemotherapy to the expression of Cerb-B2 in patients with breast cancer

作　　者：高小康[1] 孙鹤庆[1] 

机构地区：[1]扬州市第一人民医院乳腺外科,江苏扬州225001

出　　处：《现代医学》2013年第11期787-791,共5页Modern Medical Journal

摘　　要：目的：探讨新辅助化疗对乳腺癌人表皮生长因子受体-2（Cerb-B2）表达的影响及Cerb-B2的变化与新辅助化疗临床疗效的相关性,从而明确新辅助化疗后Cerb-B2表达改变的临床意义。方法：选取2010年至2012年经空心针穿刺病理诊断明确的乳腺癌患者70例予以新辅助化疗,通过免疫组化法分别检测化疗前后乳腺癌组织中Cerb-B2的表达。化疗方案（TT方案）：多西紫杉醇（艾素）70 mg·m^-2第1天,吡柔比星60 mg第1天,21 d为1个周期,经过2-4个周期新辅助化疗,评估化疗疗效,再行乳腺癌改良根治术或保乳手术,比较化疗前后Cerb-B2表达的变化,分析Cerb-B2表达的变化与化疗疗效的相关性。结果：70例乳腺癌新辅助化疗病例中,化疗前后Cerb-B2均过度表达13例（A组）;化疗前过度表达,化疗后未过度表达16例（B组）;化疗前未过度表达,化疗后过度表达7例（C组）;化疗前后均未过度表达34例（D组）。新辅助化疗前后Cerb-B2的表达差异有统计学意义（P〈0.05）,Cerb-B2过度表达和未过度表达患者疗效比较差异无统计学意义（P=1.0）。4个亚组间疗效比较差异无统计学意义（P=0.589）。结论：新辅助化疗能改变Cerb-B2的表达状态,但是新辅助化疗疗效与乳腺癌患者的Cerb-B2表达状态无明显相关性,同时新辅助化疗前后Cerb-B2的改变与疗效亦无明显相关性。Objective：To study the influence of Neo-adjuvant chemotherapy（ NAC） on the expression of Cerb-B2in patients with breast cancer and its correlation with clinical curative effects. Methods： From 2010 to 2012 the Cerb-B2 expression before and after NAC of 70 patients with breast cancer were detected by immunohistochemistry.The neo-adjuvant chemotherapy regimen（ TT regimen） was taxotere 70 mg·m^-2in day one,pirarubicin 60 mg in day one for 21 days as one cycle. After 2-4 cycles,the patients were underwent surgical operation. The changes of Cerb-B2 expression before and after NAC were compared and its correlation with NAC＇s clinical curative effects was analyzed. Results：Among the 70 patients,13 cases（group A）kept the expression of Cerb-B2 overexpression,16 cases（ group B） showed a transformation of the expression of Cerb- B2 from overexpression to nonoverexpressed,7 cases（ group C） showed a transformation of the expression of Cerb-B2 from non-overexpressed to overexpression,34 cases（ group D） kept the expression of Cerb-B2 non-overexpressed,with statistical alteration for Cerb-B2 status due to NAC（ P 0. 05）,and non-statistical diversity for therapeutic effects between Cerb-B2overexpression and non-overexpressed patients（ P = 1. 0） and between the four groups（ P = 0. 589）. Conclusion：NAC can change the Cerb-B2 expression status in patients with breast cancer,but it is not statistically related to clinical performance of NAC,and there is no relationship between the Cerb-B2 expression status and NAC neither.

关 键 词：乳腺癌 新辅助化疗 人表皮生长因子受体-2 表达 

分 类 号：R737.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]